Take the Diabetes Health Pump Survey
See What's Inside
Read this FREE issue now
For healthcare professionals only
  • 12 Tips for Traveling With Diabetes
See the entire table of contents here!

You can view the current or previous issues of Diabetes Health online, in their entirety, anytime you want.
Click Here To View

See if you qualify for our free healthcare professional magazines. Click here to start your application for Pre-Diabetes Health, Diabetes Health Pharmacist and Diabetes Health Professional.

Learn More About the Professional Subscription

Free Diabetes Health e-Newsletter
Latest
Popular
Top Rated
Diabetes Health Archives
Print | Email | Share | Comments (0)

Two New Promising Type 2 Drugs in the Pipeline


May 19, 2013

Two new drugs originally developed by Eli Lilly are showing promise when it comes to treating type 2 diabetes.

Both drugs are injectable glucagon-like peptides (amino acids) designed to be used once a week.

The first is dulaglutide, which after five studies ranging in length from 52 to 108 weeks, was shown to reduce A1c levels more successfully than comparable drugs, including Bristol-Myers Squib Co.’s Byetta, Merck & Co.’s Januvia, and metformin.

It was also shown to work as well as insulin when it comes to controlling blood glucose levels.

The company is hoping to submit data from the studies to U.S. regulatory authorities this year seeking marketing approval for the new drug.

The second drug, TT-401, showed significant improvement in both blood glucose control and reduction in body weight, according to the results of a study by Transition Therapeutics Inc., a biopharmaceutical company based in Toronto, Canada.

“We are very pleased with the proof of concept data from this study,” said Aleksandra Pastrak, vice president of clinical development and medical officer at Transition. “These data support a clear development path forward to a larger Phase 2 study of TT-401.”

The study was conducted with both those with diabetes and those without, but the drug was used in conjunction with metformin in all diabetes patients.

Over the course of the study, the biggest side effect was loss of appetite, followed by mild nausea and vomiting, which is common in drugs of this type, researchers said.

Transition secured the rights to the drug TT-401 in 2010 from Eli Lilly and Co., and will release it, pending approval, through Lilly.


Categories: A1C, Diabetes, Diabetes Health, Diabetic, Eli Lilly & Co, Research, Type 2 Issues



You May Also Be Interested In...


Comments


Add your comments about this article below. You can add comments as a registered user or anonymously. If you choose to post anonymously your comments will be sent to our moderator for approval before they appear on this page. If you choose to post as a registered user your comments will appear instantly.

When voicing your views via the comment feature, please respect the Diabetes Health community by refraining from comments that could be considered offensive to other people. Diabetes Health reserves the right to remove comments when necessary to maintain the cordial voice of the diabetes community.

For your privacy and protection, we ask that you do not include personal details such as address or telephone number in any comments posted.

Don't have your Diabetes Health Username? Register now and add your comments to all our content.

Have Your Say...


Username: Password:
Comment:
©1991-2014 Diabetes Health | Home | Privacy | Press | Advertising | Help | Contact Us | Donate | Sitemap

Diabetes Health Medical Disclaimer

The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. All content, including text, graphics, images, and information, contained on or available through this website is for general information purposes only. Opinions expressed here are the opinions of writers, contributors, and commentators, and are not necessarily those of Diabetes Health. Never disregard professional medical advice or delay seeking medical treatment because of something you have read on or accessed through this website.